



UNITED STATES PATENT AND TRADEMARK OFFICE

JAN 21 2011

Commissioner for Patents  
United States Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

Office of Regulatory Policy  
Food and Drug Administration  
10903 New Hampshire Ave., Bldg. 51, Rm. 6222  
Silver Spring, MD 20993-0002

Attention: Beverly Friedman

Dear Ms. Axelrad:

Transmitted herewith is a copy of the application for patent term extension of U.S. Patent No. 5,540,938. The application was filed on March 17, 2010, under 35 U.S.C. § 156. Please note that applicant also filed for patent term extension for NDA 22-0250 in U.S. Patent No. 5,370,879 (FDA-2010-E-0484), pursuant to 37 C.F.R. § 1.785.

The patent claims a product that was subject to regulatory review under the Federal Food, Drug and Cosmetic Act. Subject to final review, the subject patent is considered to be eligible for patent term extension. Thus, a determination by your office of the applicable regulatory review period is necessary. Accordingly, notice and a copy of the application are provided pursuant to 35 U.S.C. § 156(d)(2)(A).

Inquiries regarding this communication should be directed to the undersigned at (571) 272-7755 (telephone) or (571) 273-7755 (facsimile).

Mary C. Tilly  
Senior Legal Advisor  
Office of Patent Legal Administration  
Office of the Associate Commissioner  
for Patent Examination Policy

cc: Christopher N. Sipes  
Covington & Burling LLP  
1201 Pennsylvania Ave. N.W.  
Washington DC 20004-2401

RE: AMPYRA® (daldampridine)  
Docket No. FDA-2010-E-0483